Medical Information Search

Coronavirus (COVID-19) and the Use of CIMZIA® (certolizumab pegol)

Read important information related to your request

The material below is provided in response to your specific search for information on UCBCOMPASS® IMMUNOLOGY and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. See FDA-approved indications  .

CIMZIA® is associated with a BOXED WARNING regarding serious infections and malignancy and important WARNINGS AND PRECAUTIONS, including heart failure, anaphylaxis or serious allergic reactions, hepatitis B virus reactivation, demyelinating disease, cytopenias or pancytopenia, and Lupus-like syndrome.

Please review the Full Prescribing Information here.

This material is not for distribution or reproduction.

Current View
Was this content helpful?
1000 characters remaining
To report a suspected adverse event or product
quality complaint, please complete our online webform. Your may also contact ucbCARES® at
1-844-599-CARE (2273) or email ucbcares@ucb.com
To report a suspected adverse event or product
quality complaint, please complete our online webform. Your may also contact ucbCARES® at
1-844-599-CARE (2273) or email ucbcares@ucb.com